

Jae-Hyun Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11906362/publications.pdf>

Version: 2024-02-01

58
papers

3,333
citations

147801

31
h-index

149698

56
g-index

58
all docs

58
docs citations

58
times ranked

5819
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance. <i>Cancer Cell</i> , 2012, 21, 488-503.	16.8	419
2	Myasthenic crisis and polymyositis induced by one dose of nivolumab. <i>Cancer Science</i> , 2016, 107, 1055-1058.	3.9	176
3	Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays. <i>Clinical Cancer Research</i> , 2004, 10, 272-284.	7.0	169
4	PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 9186-9195.	0.9	164
5	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. <i>Breast Cancer Research</i> , 2007, 9, R17.	5.0	150
6	Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide N-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 2759-2769.	0.9	146
7	Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1342-1353.	1.3	127
8	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1204507.	4.6	107
9	Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells. <i>Cancer Research</i> , 2009, 69, 8752-8760.	0.9	106
10	TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. <i>Science Translational Medicine</i> , 2014, 6, 259ra145.	12.4	95
11	Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. <i>Cancer Science</i> , 2008, 99, 62-70.	3.9	94
12	Polypeptide N-acetylgalactosaminyltransferase 6 Disrupts Mammary Acinar Morphogenesis through O-glycosylation of Fibronectin. <i>Neoplasia</i> , 2011, 13, 320-IN10.	5.3	88
13	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	1.8	83
14	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	7.0	70
15	Critical roles of T-LAK cell-originated protein kinase in cytokinesis. <i>Cancer Science</i> , 2010, 101, 403-411.	3.9	68
16	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117.	7.0	63
17	The E-cadherin -347G>A promoter polymorphism and its effect on transcriptional regulation. <i>Carcinogenesis</i> , 2004, 25, 895-899.	2.8	62
18	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. <i>Human Genetics</i> , 2003, 114, 118-120.	3.8	61

#	ARTICLE	IF	CITATIONS
19	Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. <i>Cancer Science</i> , 2009, 100, 1468-1478.	3.9	54
20	Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1278330.	4.6	54
21	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. <i>Oncolmmunology</i> , 2015, 4, e1030561.	4.6	52
22	Germline mutations ofBRCA1 andBRCA2 in Korean breast and/or ovarian cancer families. <i>Human Mutation</i> , 2002, 20, 235-235.	2.5	47
23	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. <i>Oncotarget</i> , 2018, 9, 11009-11019.	1.8	44
24	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. <i>Oncotarget</i> , 2016, 7, 17652-17664.	1.8	44
25	Involvement of Gâ€patch domain containing 2 overexpression in breast carcinogenesis. <i>Cancer Science</i> , 2009, 100, 1443-1450.	3.9	41
26	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13621-13633.	1.8	41
27	Effects of <sc>SMYD</sc>-mediated <sc>EML</sc>-<sc>ALK</sc> methylation on the signaling pathway and growth in nonâ€smallâ€cell lung cancer cells. <i>Cancer Science</i> , 2017, 108, 1203-1209.	3.9	38
28	Critical roles of SMYD2-mediated Î²-catenin methylation for nuclear translocation and activation of Wnt signaling. <i>Oncotarget</i> , 2017, 8, 55837-55847.	1.8	37
29	A functional polymorphism (-347 G->GA) in the E-cadherin gene is associated with colorectal cancer. <i>Carcinogenesis</i> , 2004, 25, 2173-2176.	2.8	36
30	WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. <i>Scientific Reports</i> , 2017, 7, 40664.	3.3	36
31	p53-independent p21 induction by MELK inhibition. <i>Oncotarget</i> , 2017, 8, 57938-57947.	1.8	35
32	Characterization of the cryoablation-induced immune response in kidney cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1326441.	4.6	34
33	WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 0, 7, 42527-42538.	1.8	33
34	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
35	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1568813.	4.6	31
36	Presence of Insulin-Like Growth Factor Binding Proteins Correlates With Tumor-Promoting Effects of Matrix Metalloproteinase 9 in Breast Cancer. <i>Neoplasia</i> , 2015, 17, 421-433.	5.3	28

#	ARTICLE	IF	CITATIONS
37	<sc>TOPK</sc> (Tâ€<sc>LAK</sc> cellâ€originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 488-496.	3.9	28
38	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. <i>Oncotarget</i> , 2017, 8, 62029-62038.	1.8	28
39	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. <i>Neoplasia</i> , 2016, 18, 265-272.	5.3	27
40	Establishment and characterization of cell lines from three human thyroid carcinomas: Responses to all-trans-retinoic acid and mutations in the BRAF gene. <i>Molecular and Cellular Endocrinology</i> , 2007, 264, 118-127.	3.2	25
41	GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition. <i>Neoplasia</i> , 2017, 19, 43-53.	5.3	23
42	T-LAK cell-originated protein kinase presents a novel therapeutic target in<i>FLT3</i>-ITD mutated acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 33410-33425.	1.8	22
43	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2018, 201, 1967-1974.	0.8	22
44	Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 507-516.	4.1	22
45	Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2017, 23, 4897-4907.	7.0	21
46	Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. <i>Oncotarget</i> , 2018, 9, 31820-31831.	1.8	17
47	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1588085.	4.6	17
48	Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells. <i>Neoplasia</i> , 2018, 20, 1038-1044.	5.3	15
49	The era of immunogenomics/immunopharmacogenomics. <i>Journal of Human Genetics</i> , 2018, 63, 865-875.	2.3	15
50	Development of small molecular compounds targeting cancer stem cells. <i>MedChemComm</i> , 2017, 8, 73-80.	3.4	14
51	Potent antiâ€myeloma activity of the TOPK inhibitor OTS514 in preâ€clinical models. <i>Cancer Medicine</i> , 2020, 9, 324-334.	2.8	14
52	MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells. <i>Oncology Reports</i> , 2019, 41, 2540-2548.	2.6	12
53	Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. <i>Human Molecular Genetics</i> , 2018, 27, 2671-2677.	2.9	11
54	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11

#	ARTICLE	IF	CITATIONS
55	The GALNT6â€LGALS3BP axis promotes breast cancer cell growth. International Journal of Oncology, 2020, 56, 581-595.	3.3	9
56	<scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Reports, 2018, 1, e1002.	1.4	8
57	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. Oncotarget, 2018, 9, 3805-3814.	1.8	6
58	Activation of an Estrogen/ Estrogen Receptor Signaling by BIG3 Through Its Inhibitory Effect on Nuclear Transport of PHB2/REA in Breast Cancer. Nature Precedings, 2009, , .	0.1	1